United States Cancer Biomarkers Market Size, Share and Forecast Trends - Growth Analysis and Outlook Report 2026-2030

Cancer biomarkers are biological molecules found in blood, tissues, or other body fluids that signal normal or abnormal processes, playing a critical role in early cancer detection, prognosis, and treatment monitoring. The U.S. represents the largest single-country market globally, fueled by high healthcare spending, strong R&D infrastructure, and a growing burden of cancer cases. Biomarker-based companion diagnostics, in particular, have become integral to targeted therapy pipelines across oncology.

• •Market valued at ~$11.23 billion in 2025 with a CAGR of 10.9% through the early 2030s
• •Strong pipeline of FDA-approved biomarker-based companion diagnostics supporting targeted therapies
• •Liquid biopsy and multi-cancer early detection tests are emerging high-growth sub-segments

Rising cancer prevalence, projected to affect over 2 million new patients annually in the U.S., is the primary demand driver, alongside an aging population more susceptible to oncology conditions. Advances in genomics, proteomics, and AI-driven biomarker discovery are expanding the catalog of clinically actionable targets. Supportive regulatory frameworks and favorable reimbursement policies for FDA-approved companion diagnostics further accelerate adoption.

• •Growing emphasis on precision medicine and personalized treatment regimens in oncology
• •Increasing adoption of minimally invasive liquid biopsy technologies over traditional tissue biopsies
• •Favorable reimbursement landscape for FDA-approved companion diagnostic tests

The market is segmented by biomarker type, proteomic, genomic, epigenomic, and metabolomic, as well as by cancer type (lung, breast, colorectal, prostate, and others) and application (diagnostics, prognosis, drug development). The U.S. dominates the North American region due to advanced healthcare infrastructure, higher testing rates, and concentrated biopharmaceutical activity. Within the U.S., major metropolitan areas and academic medical centers drive disproportionate adoption of novel biomarker technologies.

• •Genomic biomarkers represent the largest segment, fueled by NGS and PCR-based technologies
• •Lung and breast cancers account for the highest biomarker testing volumes
• •North America leads globally, with the U.S. comprising the dominant share within the region

What are the recent trends and outlook?

Multi-cancer early detection (MCED) blood tests leveraging circulating tumor DNA represent one of the most dynamic innovation areas, with the potential to significantly expand screening populations. AI and machine learning are increasingly applied to biomarker discovery and result interpretation, improving sensitivity and specificity. Over the forecast horizon, integration of biomarkers into routine clinical workflows, expansion into underserved cancer types, and real-world evidence generation will shape the market's next phase of growth.

• •MCED liquid biopsy tests are expected to drive new revenue streams and shift screening paradigms
• •AI-powered biomarker discovery platforms are accelerating identification of novel cancer signals
• •Increasing regulatory acceptance of biomarker-based endpoints in clinical trials